Takeshita and coworkers reached a similar conclusion, who explored a group of early and late, metastatic ER+ breast cancer patients and showed that PIK3CA mutations, detected on circulating plasma DNA, were not associated with clinical outcome [303]. The gene discussed is PIK3CA; the disease is breast carcinoma.